The Value of a QofE Beyond Standard EBITDA Normalizations
The Value of a QofE Beyond Standard EBITDA Normalizations
| Topic | EBITDA Normalization & QofE |
| Audience | PE Sponsors, Deal Teams, CFOs, Lenders |
| Stage | Pre-LOI Through Due Diligence |
| Applies To | Middle Market M&A Transactions |
- EBITDA normalization removes non-recurring items from reported earnings, but it does not assess whether the revenue and margins that remain are sustainable or accurately presented.
- Seller-prepared normalization adjustments are frequently overstated and require independent verification before they can be relied upon in valuation or debt underwriting.
- A Quality of Earnings review goes further: it evaluates revenue quality, customer concentration, accounting policy, working capital, and the assumptions behind management's projections.
- At 7x to 10x EBITDA multiples, a $500,000 overstatement in adjusted EBITDA translates directly into $3.5 to $5 million in purchase price exposure.
Every middle market PE transaction arrives with a seller-prepared adjusted EBITDA bridge. The logic is familiar: remove the owner's personal expenses, add back a one-time legal charge, normalize for a non-recurring contract, and present the result as the business's true run-rate earnings. This process is necessary. The problem is that deal teams too often treat it as sufficient.
EBITDA normalization answers one question: what should be removed from reported earnings? It does not evaluate whether the revenue underlying those earnings is concentrated in one or two customers with expiring contracts, whether the company's revenue recognition policies are conservative or aggressive, or whether growing the business will require working capital that compresses free cash flow well below what the EBITDA multiple implies. Those questions require a Quality of Earnings review, and when sponsors skip that step, they are underwriting against a number they have not fully tested.
Where Normalization Falls Short
Seller adjustments, including excess owner compensation, one-time costs, and pro forma revenue from contracts under negotiation, are almost always presented optimistically. Independent QofE work routinely finds that a meaningful share of seller-presented add-backs are either partially supportable or unsupported when subjected to documentary review.
At an 8x purchase price multiple, a $750,000 reduction in independently supportable EBITDA represents $6 million in overpayment. That gap does not close through post-close operational improvement, as it is locked into the deal structure at signing.
Beyond the adjustments themselves, normalization leaves the most consequential risks unexamined. Revenue concentration, contract renewal risk, aggressive cost capitalization, and working capital dynamics that imply a cash-consumptive business at growth, none of these appear in a normalization bridge. They appear in a QofE review, and they routinely change how a sponsor structures a deal, prices leverage, or sizes a working capital peg.
What a QofE Review Actually Provides
A Quality of Earnings engagement independently verifies the normalization adjustments, then goes further: it disaggregates revenue by customer and contract to assess concentration and renewal risk, evaluates whether accounting policies are consistent with applicable standards, calculates a normalized working capital requirement, and tests management's projections against historical performance. The result is an independently supported EBITDA figure that a deal team, and its lenders, can underwrite against with confidence.
The cost of a QofE review is small relative to the exposure it addresses. The transactions most likely to underperform are not those in which due diligence surfaced a problem. They are the ones in which the sponsor relied on normalized EBITDA and discovered the gap only after close.
Summary
EBITDA normalization is a necessary step in PE deal analysis, but it is not a substitute for a Quality of Earnings review. Normalization removes non-recurring items; it does not assess the quality or sustainability of what remains. In middle market transactions priced at 7x to 10x EBITDA, the difference between seller-adjusted and independently supported earnings has direct and material consequences for purchase price, leverage, and post-close performance. A QofE engagement provides the independent verification and broader analytical coverage that normalization alone cannot.
The Value of a QofE Beyond Standard EBITDA Normalizations
The Value of a QofE Beyond Standard EBITDA Normalizations
Every middle market PE transaction arrives with a seller-prepared adjusted EBITDA bridge. The logic is familiar: remove the owner's personal expenses, add back a one-time legal charge, normalize for a non-recurring contract, and present the result as the business's true run-rate earnings. This process is necessary. The problem is that deal teams too often treat it as sufficient.
EBITDA normalization answers one question: what should be removed from reported earnings? It does not evaluate whether the revenue underlying those earnings is concentrated in one or two customers with expiring contracts, whether the company's revenue recognition policies are conservative or aggressive, or whether growing the business will require working capital that compresses free cash flow well below what the EBITDA multiple implies. Those questions require a Quality of Earnings review, and when sponsors skip that step, they are underwriting against a number they have not fully tested.
Where Normalization Falls Short
Seller adjustments, including excess owner compensation, one-time costs, and pro forma revenue from contracts under negotiation, are almost always presented optimistically. Independent QofE work routinely finds that a meaningful share of seller-presented add-backs are either partially supportable or unsupported when subjected to documentary review.
At an 8x purchase price multiple, a $750,000 reduction in independently supportable EBITDA represents $6 million in overpayment. That gap does not close through post-close operational improvement, as it is locked into the deal structure at signing.
Beyond the adjustments themselves, normalization leaves the most consequential risks unexamined. Revenue concentration, contract renewal risk, aggressive cost capitalization, and working capital dynamics that imply a cash-consumptive business at growth, none of these appear in a normalization bridge. They appear in a QofE review, and they routinely change how a sponsor structures a deal, prices leverage, or sizes a working capital peg.
What a QofE Review Actually Provides
A Quality of Earnings engagement independently verifies the normalization adjustments, then goes further: it disaggregates revenue by customer and contract to assess concentration and renewal risk, evaluates whether accounting policies are consistent with applicable standards, calculates a normalized working capital requirement, and tests management's projections against historical performance. The result is an independently supported EBITDA figure that a deal team, and its lenders, can underwrite against with confidence.
The cost of a QofE review is small relative to the exposure it addresses. The transactions most likely to underperform are not those in which due diligence surfaced a problem. They are the ones in which the sponsor relied on normalized EBITDA and discovered the gap only after close.
Summary
EBITDA normalization is a necessary step in PE deal analysis, but it is not a substitute for a Quality of Earnings review. Normalization removes non-recurring items; it does not assess the quality or sustainability of what remains. In middle market transactions priced at 7x to 10x EBITDA, the difference between seller-adjusted and independently supported earnings has direct and material consequences for purchase price, leverage, and post-close performance. A QofE engagement provides the independent verification and broader analytical coverage that normalization alone cannot.
RECENT NEWS
Monthly Middle Market M&A Insider Report (Aug 2026)
The McLean Group’s August 2026 M&A Insider Report tracks deal activity across Defense & Government, Physical & Cyber Security, Critical Infrastructure, and Maritime. This month’s edition highlights notable transactions including Motorola Solutions’ $1.5B acquisition of D-Fend Solutions, adding RF cyber-takeover counter-drone technology deployed in more than 30 countries, AE Industrial Partners’ $845M carve-out of L3Harris’ space propulsion, power and electronics units, which re-establishes the business as a standalone company under the revived Rocketdyne name, and Booz Allen Hamilton’s $720M acquisition of the Ultra I&C Mission Solutions business from Advent-backed Cobham Ultra Group. The report also includes public company trading comps and EBITDA valuation multiples across all four sectors. Public market multiples are provided for reference purposes and reflect traded equity values, which may differ materially from private company transaction pricing. […]
The McLean Group Advises Valiant O&M on Its Acquisition by Inspirit Equity
The McLean Group advises Valiant O&M, the operations and maintenance division of Valiant, on its acquisition by Inspirit Equity, a Los Angeles-based private investment firm backed by permanent capital. Now operating independently as Vulcan Government Services, the business provides facility operations, maintenance, and logistics services to U.S. government agencies, supporting hospitals, research laboratories, and other critical infrastructure through a diversified portfolio of long-term contracts. […]
Backlog as a Diligence KPI: Funded, Unfunded, and What Buyers Actually Underwrite
Backlog is the bridge between a company’s historical financial performance and management’s forecast, but only the funded portion carries the certainty a buyer will actually underwrite. In this article, The McLean Group’s Financial Consulting team examines what backlog is and is not, how funded and unfunded commitments differ, and the four measures diligence teams test: coverage, burn, attrition, and concentration. For owners approaching a sale process, a backlog record that predates the process gives sellers control of the assumptions behind their forecast. […]